Financial Performance and Operating Leverage in Selected Indian Pharmaceutical Firms

This descriptive study examines how revenue growth, operating profitability and the observed sensitivity of EBITDA to revenue differ across five purposively selected listed Indian pharmaceutical firms (Piramal Pharma, Ajanta Pharma, Laurus Labs, Neuland Laboratories and Innova Captab) over FY2022–FY2026, and analyses Piramal Pharma’s FY2026 results in more detail. It uses audited consolidated results, revenue CAGRs, calculated EBITDA margins (excluding other income), margin variability, an ex post EBITDA-based operating-leverage proxy and a DuPont decomposition of return on equity. Revenue CAGRs ranged from 7.8% to 20.8%. Mean calculated EBITDA margins were 25.9% (Ajanta), 23.6% (Neuland) and 23.1% (Laurus), against 13.7% (Innova) and 12.8% (Piramal). Firms described as having stronger differentiated capabilities generally recorded higher average margins; this association does not establish causality. In FY2026 Piramal’s company-reported EBITDA fell 28.2% on a 3.1% revenue decline and PAT turned to a loss of INR 326 crore; an EBITDA-to-PAT bridge shows several contributing items, and return on average equity fell from 1.14% to −4.00%, mainly through net margin. Findings are limited to the sample, and MSME evidence is treated as context only.

Authors

Publication Details

Journal
International Journal of Creative and Open Research in Engineering and Management
Published
2026-11-17
DOI
https://doi.org/10.55041/ijcope.v2i11.093
Primary Topic
Financial Analysis and Corporate Governance
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Financial Performance and Operating Leverage in Selected Indian Pharmaceutical Firms

Shirly Abraham, Adit Vijay Bhoite
2 links
International Journal of Creative and Open Research in Engineering and Management
Financial Analysis and Corporate Governance
article

Financial Performance and Operating Leverage in Selected Indian Pharmaceutical Firms

Shirly Abraham, Adit Vijay Bhoite
article en

Abstract

This descriptive study examines how revenue growth, operating profitability and the observed sensitivity of EBITDA to revenue differ across five purposively selected listed Indian pharmaceutical firms (Piramal Pharma, Ajanta Pharma, Laurus Labs, Neuland Laboratories and Innova Captab) over FY2022–FY2026, and analyses Piramal Pharma’s FY2026 results in more detail. It uses audited consolidated results, revenue CAGRs, calculated EBITDA margins (excluding other income), margin variability, an ex post EBITDA-based operating-leverage proxy and a DuPont decomposition of return on equity. Revenue CAGRs ranged from 7.8% to 20.8%. Mean calculated EBITDA margins were 25.9% (Ajanta), 23.6% (Neuland) and 23.1% (Laurus), against 13.7% (Innova) and 12.8% (Piramal). Firms described as having stronger differentiated capabilities generally recorded higher average margins; this association does not establish causality. In FY2026 Piramal’s company-reported EBITDA fell 28.2% on a 3.1% revenue decline and PAT turned to a loss of INR 326 crore; an EBITDA-to-PAT bridge shows several contributing items, and return on average equity fell from 1.14% to −4.00%, mainly through net margin. Findings are limited to the sample, and MSME evidence is treated as context only.

International Journal of Creative and Open Research in Engineering and ManagementVol. 02(11)
Good health and well-being
Financial Analysis and Corporate Governance
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon